The first Glint product, MoxiLens™, is an antibiotic releasing contact lens.

CAMBRIDGE, MA, May 04, 2023 /24-7PressRelease/ — Glint Pharmaceuticals will present its drug releasing contact lens technology at the annual Eyecelerator 2023 conference, in San Diego, CA on May 4, 2023. The Eyecelerator marketplace conference is a leading venue for innovative companies in ophthalmology to present clinical and scientific advances to practicing ophthalmologists and industry executives.

The first Glint product, MoxiLens™, is an antibiotic releasing contact lens. The target market for an effective and convenient treatment for corneal infection and injury includes more than 10 million patients in the US and EU. The current standard of care requires the patient to administer antibiotic eye drops on a frequent basis over several days to treat the ocular infection. The Glint lens will eliminate the need for most patients to use antibiotic eye drops. Replacing the need for patients to apply eye drops will increase compliance and may lead to better therapeutic outcomes.

Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include eye infections and corneal abrasions, glaucoma, post-surgical ocular inflammation, allergic conjunctivitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The patented Glint technology has the potential to increase drug efficacy and improve patient compliance. The contact lens technology is licensed to Glint from the University of Florida.

For the original version of this press release, please visit here